Acorda Drops Epilepsy Candidate Once Central To Its Revenue Forecasts

Plumiaz, a nasal spray formulation of diazepam, is discontinued after it fails one of three Phase III trials undertaken to comply with 2014 FDA complete response letter.

Cited up until very recently by Acorda Therapeutics Inc. as one of four late-stage pipeline candidates that would dramatically increase the company's product sales, the Phase III Plumiaz is being discontinued after it failed to demonstrate bioequivalence to the reference product.

The Ardsley, N.Y., biotech announced its decision May 20, noting that its nasal spray formulation of diazepam did not demonstrate...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip